- Actual raw data does NOT show C-Reactive Protein increasing with vitamin D (but it does increase when adjusted for obesity)
- Even after data manipulation by the study, the increase in C-Reactive Protein at 50 ng of vitamin D is tiny
- C-Reactive Protein test results have a huge variability – even with the same patient (see graph below)
- C-Reactive Protein test is not universally agreed to be a predictor of heart problems
– – – – – – – – – –
The raw data shows a increase in C-Reactive Protein with obesity.
Only when the data has been adjusted (polite term for manipulated) for 10 other factors did the small vitamin D association turn up
(Thanks to Dr. L Baggerly at GrassRootsHealth for pointing this out in personal communication, which he is publishing as a response to the original paper)
– – – – – – – – –
"The projected increase in CRP concentration in the adjusted model is only 0.033 mg/dl or 0.33 mg/L"
Say, for example, from 1.0 to 1.033 mg/dl
Additionally, we observed a positive relation between 25(OH)D above its median and CRP [geometric mean CRP change
0.06 mg/dl for each 10-ng/ml change in 25(OH)D, 95% CI 0.02 to 0.11) after adjusting for traditional cardiovascular risk factors.
– – – – – – – – – – –
Note: the "predicted" increase due to a lot of vitamin D is 0.033 mg/dl = 0.33 mg/LITER - about 1/2 the height of a dot.
– – – – – – – – – – –
Positive Association Between 25-Hydroxyvitamin D and C-Reactive Protein is Confounded by Hormonal Contraceptive Use.
J Womens Health (Larchmt). 2013 May;22(5):417-25. doi: 10.1089/jwh.2012.4046.
García-Bailo B, Josse AR, Jamnik J, Badawi A, El-Sohemy A.
1 Department of Nutritional Sciences, Faculty of Medicine, University of Toronto , Toronto, Canada .
Background: Studies of the relationship between vitamin D and inflammation are equivocal. This may be due to unaccounted confounding. Hormonal contraceptive (HC) use is associated with elevated circulating 25-hydroxyvitamin D [[25(OH)D] in Caucasians and African-Americans, but its effects on 25(OH)D in other ethnicities are unclear. HC use is associated with elevated C-reactive protein (CRP), an inflammatory biomarker. Our objectives were to assess the effect of HC use on 25(OH)D across ethnic groups, and to examine the association between HC, 25(OH)D and CRP in an ethnically diverse population of young adults.
Methods: We recruited Caucasian, East Asian, and South Asian individuals (n=1,403) from Toronto, Canada. Fasting blood measures of 25(OH)D and CRP were obtained.
Results: Across ethnic groups, women HC users (n=280) had higher 25(OH)D and CRP than women HC non-users (n=695) and men (n=428) (p<0.008 and p<0.0001, respectively). Circulating 25(OH)D was positively associated with CRP in the entire population in models not accounting for HC use (β=0.010±0.003; p<0.0001). There was no association when men and women HC non-users were examined separately. Among women HC users, there was no association after accounting for hormone dose. A positive association between 25(OH)D and CRP among individuals above the median 25(OH)D (≥51.9 nmol/L) was not significant after adjustment for HC use. No association was observed among individuals below the median.
Conclusions: HC use and 25(OH)D were positively associated across ethnic groups.
We found no association between 25(OH)D and CRP when HC use was accounted for.
HC use confounds the association between 25(OH)D and CRP.
Reported by the New York Times, and about 50 other sources on the internet
CLICK HERE for Vitamin D Council comment on the paper